Chronic rejection, operatively defined as obliterative thickening of tubular structures such as graft vasculature, has become an intractable problem despite any current, otherwise effective, immunosuppression used in the management of transplant (Tx) recipients. A hallmark of chronic cardiac rejection is accelerated or Tx arteriosclerosis, characterized by diffuse intimal thickening due to the initial accumulation of macrophages (MO), followed by smooth muscle cells (SMC). Based on in vitro and some descriptive in vivo studies, the pathogenesis of Tx arteriosclerosis is thought to involve T cell recognition of donor MHC antigens expressed by endothelial leukocyte adhesion molecules, chemotaxis and activation of MO. Local elaboration of pro-inflammatory cytokines, and recruitment and proliferation of medial-derived SMC within the intima. Though, collectively, these events involve activation of many genes and complex intracellular pathways, most, if not all, such steps involve activation of the transcriptional factor, NFkB. Indeed, in vitro studies have led to a new paradigm in which NFkB is the critical regulator of multiple genes activated during inflammatory or immunologic responses. Thus, NFkB is considered essential to the induction of IL-2 and IL-2R in T cells; Ig synthesis by B cells; IL-1 and TNFalpha in MO; IFNg in NK cells; IL-1alpha and beta, IL-6, IL-8, MCP-1, E-selectin, ICAM-1 and VCAM- 1 in EC; and cell-matrix interactions in fibroblasts and smooth muscle cells. However, due to a lack of suitable and specific inhibitors of the NFkB pathway, little has been done towards testing this knowledge in vivo, including in the context of allograft recipients and Tx arteriosclerosis. We have developed a model of chronic cardiac allograft rejection in the mouse in which long-term allograft survival is achieved by brief CD4 monoclonal antibody (mAb) therapy post-Tx, albeit with a concomitant development of severe Tx arteriosclerosis. We propose to use this model to identify the mechanisms responsible for development of chronic rejection, focusing on the use of transgenic mice expressing a tetracycline-sensitive inhibitor of the transcription factor, NFkB. This novel system should function as a conditional NFkB/Rel """"""""knockout"""""""", in which expression of the inhibitor can be regulated by tetracycline and allow shutdown of NFkB activity at any stage of the experimental protocol. Thus, analysis of these mice should provide the first direct in vivo evidence as to the role of the NFkB pathway, and potentially lead to the development of important new therapeutic strategies of direct relevance to Tx recipients.

Project Start
2000-08-01
Project End
2002-07-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
2000
Total Cost
$184,511
Indirect Cost
Name
Harvard University
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Gasser, Martin; Waaga-Gasser, Ana Maria; Grimm, Michael W et al. (2005) Selectin blockade plus therapy with low-dose sirolimus and cyclosporin a prevent brain death-induced renal allograft dysfunction. Am J Transplant 5:662-70
Lee, Iris; Wang, Liqing; Wells, Andrew D et al. (2005) Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 201:1037-44
Tao, Ran; Wang, Liqing; Han, Rongxiang et al. (2005) Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J Immunol 175:5774-82
Lee, Iris; Wang, Liqing; Wells, Andrew D et al. (2003) Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 171:6929-35
Sho, Masayuki; Harada, Hiroshi; Rothstein, David M et al. (2003) CD45RB-targeting strategies for promoting long-term allograft survival and preventingchronic allograft vasculopathy. Transplantation 75:1142-6
Hancock, Wayne W; Gao, Wei; Shemmeri, Nida et al. (2002) Immunopathogenesis of accelerated allograft rejection in sensitized recipients: humoral and nonhumoral mechanisms. Transplantation 73:1392-7
Yuan, Xueli; Dong, Victor M; Coito, Ana J et al. (2002) A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection. Transplantation 73:1736-42
Ye, Qunrui; Fraser, Christopher C; Gao, Wei et al. (2002) Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 195:795-800
Gasser, Martin; Waaga, Ana Maria; Kist-Van Holthe, Joana E et al. (2002) Normalization of brain death-induced injury to rat renal allografts by recombinant soluble P-selectin glycoprotein ligand. J Am Soc Nephrol 13:1937-45
Laskowski, Igor A; Pratschke, Johann; Wilhelm, Markus J et al. (2002) Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 13:519-27

Showing the most recent 10 out of 37 publications